Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over Year

Core Insights - ImmunityBio's stock closed at $5.52, reflecting a 39.75% increase due to strong revenue growth for Anktiva, positive oncology trial results, and new regulatory approvals [1] - The trading volume surged to 176 million shares, which is approximately 1,254% higher than the three-month average of 13 million shares [2] - Preliminary 2025 net product revenue for Anktiva is projected to be around $113 million, indicating a year-over-year growth of 700% and a quarterly growth of 431% [4] Company Performance - ImmunityBio has experienced a significant decline of 85% since its IPO in 2015 [2] - The positive news regarding Anktiva and bladder cancer drug trials is expected to bolster investor confidence and attract potential investors [5] Market Context - The S&P 500 and Nasdaq Composite both saw slight declines of 0.06% [3] - Other oncology drug developers, such as Iovance Biotherapeutics and Krystal Biotech, also experienced stock price increases of 6.31% and 1.07%, respectively, indicating a broader reassessment of the oncology sector [3]